Pharma wanted pricey orphan meds, and now it’s got ’em in record numbers

Carly Helfand

New drug approvals were up last year, and drug approvals were no exception. But by just how much did they climb? The FDA Law Blog has done some digging through the agency's Orphan Drug Designations and Approvals database, and it's got an answer.

FiercePharma News

Share This Post

Related Articles

Leave a Reply

© 2019 Global Regulatory Science. All rights reserved. Site Admin · Entries RSS · Comments RSS